Medical Advocates
Zalcitabine (Hivid)
 
Main Page

New and Noteworthy
Guidelines
Database of ARV Drug Interactions
 Journal Data
Perinatal Data
 Pediatric Data




 
ARV Drugs Main Page Main New/Newsworthy Home Page      

This web page is best viewed by using INTERNET EXPLORER
Last Update:  May 10, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
       
February 2008
Journal Papers, Abstracts, and Commentaries
Pharmacokinetics Drug Interactions Resistance Adverse Events Efficacy
Pharmacokinetics
 
  FULL-TEXT ARTICLE
 Pharmacokinetics and Distribution over the Blood-Brain Barrier of Zalcitabine (2',3'-ideoxycytidine)
and BEA005 (2',3'-Dideoxy-3'-Hydroxymethylcytidine) in Rats, Studied by Microdialysis .
Borg N, Stahle L.
Antimicrob Agents Chemother 1998 Sep;42(9):2174-2177
 Paper
   
  FULL-TEXT ARTICLE
 Zalcitabine Population Pharmacokinetics: Application of Radioimmunoassay.
 Adams JM, Shelton MJ, Hewitt RG,  et al  
 Antimicrob Agents Chemother 1998 Feb;42(2):409-413
 Paper

Drug Interactions

Viral Dynamics

Resistance

  FULL-TEXT ARTICLE
 Early Virological Failure in Naive Human Immunodeficiency Virus Patients Receiving Saquinavir
(Soft Gel Capsule)-Stavudine-Zalcitabine (MIKADO Trial) Is Not Associated with Mutations Conferring
Viral Resistance.
Mouroux M, Yvon-Groussin A, Peytavin G, et al.
J Clin Microbiol 2000 Jul;38(7):2726-2730
Paper

Adverse Events

  Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or
zalcitabine.
 Walker UA, Bauerle J, Laguno M, et al.  
Hepatology. 2004 Feb;39(2):311-7.
 Abstract

Efficacy

  Management of HIV infection in Nigeria with zalcitabine in combination with saquinavir mesylate:
preliminary findings.
Akinsete I, Njoku OS, Okanny CC,et al. 
West Afr J Med 2000 Oct;19(4):265-268
 Abstract
   
  FULL-TEXT ARTICLE
 Early Virological Failure in Naive Human Immunodeficiency Virus Patients Receiving Saquinavir
(Soft Gel Capsule)-Stavudine-Zalcitabine (MIKADO Trial) Is Not Associated with Mutations
Conferring Viral Resistance.
Mouroux M, Yvon-Groussin A, Peytavin G, et al.
J Clin Microbiol 2000 Jul;38(7):2726-2730
Paper
Conference Reports, Abstracts, and Posters
         
15th CROI
 
Perinatal
Guidelines        
United States

     Internet Documents

  FULL TEXT PDF DOCUMENT
 Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs
in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce
Perinatal HIV  Transmission in the United States.
Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines
 
  FULL TEXT PDF DOCUMENT
 Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
 Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines
Pediatric Data
Guidelines Monotherapy      
Prevention/Treatment Guidelines and Recommendations

US Treatment Guidelines

Monotherapy

    Journal Papers, Abstracts, and Commentaries

  Dideoxycytidine alone and in an alternating schedule with zidovudine (AZT) in children with
symptomatic human immunodeficiency virus infection.
Pizzo PA, Butler K, Balis F et al.
Journal of Pediatrics 1990; 117: 799-808.
 Abstract
   
  Phase I evaluation of zalcitabine administered to human immunodeficiency virus-infected
children. Chadwick EG, Nazareno LA, Nieuwenhuis TJ et al.
Journal of Infectious Disease 1995; 172(6): 1475- 1479.
 Abstract
   
  Comparative trial of two dosages of zalcitabine in zidovudine- experienced children with advanced
human immunodeficiency virus disease.
Spector SA, Blanchard S, Wara DW et al. Pediatric AIDS Clinical Trials Group.
Pediatric Infectious Disease Journal 1997; 16(6): 623-626.
 Abstract

ARV Drugs Main Page Main New/Newsworthy Home Page      

Zalcitabine Main Page